€0.85
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Defence Therapeutics Inc.
sharewise wants to provide you with the best news and tools for Defence Therapeutics Inc., so we directly link to the best financial data sources.
Financials
News
EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION
EQS-News: DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
EQS-News: ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
EQS-News: DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
EQS-News: DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH
EQS-News: DEFENCE RECEIVES FDA APPROVAL FOR PHASE I CLINICAL TRIAL TARGETING SOLID CANCER TUMORS WITH ACCUTOX®
EQS-News: DEFENCE’S SUCCESSFUL SUBMISSION OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ACCUTOX® AS AN INJECTABLE ANTICANCER TREATMENT FOR SOLID TUMORS
EQS-News: DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY
EQS-News: DEFENCE’S ACCUTOX® AND ANTIGEN CROSS-PRESENTATION: DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM
Defence’s AccuTOX® Impairs Lung Cancer Growth
Vancouver, BC, Canada, January 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
Vancouver, BC, Canada, November 14th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, USOTC: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies
Defence’s AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
Vancouver, BC, Canada, April 23rd, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence’s Successful Results on its AccuTOX® Anti-Cancer ArmTM Vaccine Creates a Potent Second-Generation Anti-Cancer Arm-002TM Vaccine
Vancouver, BC, Canada, March 26th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biotechnology company developing novel
Defence Therapeutics Awarded Broad U.S. Patent Covering its Pioneering Cancer-Killing Accutox® Technology
Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with Accutox(R)
Vancouver, BC, Canada, December 12th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, USOTC: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
Vancouver, BC, Canada, November 7th, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, USOTC: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing
Defence’s AccuTOX® and Antigen Cross-Presentation: Discovery Leads towards the Development of a Groundbreaking Platform
Vancouver, BC, Canada, October 25th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading Canadian biopharmaceutical company specialized in the development of